Co-CEOs Chintu and Chirag Patel (Amneal)

Look out, Neu­las­ta: A 5th biosim­i­lar is com­ing

As Neu­las­ta sales slip, Am­gen has yet an­oth­er biosim­i­lar to look out for: Am­neal Phar­ma­ceu­ti­cals and Kashiv Bio­sciences’ Fly­ne­tra.

Fly­ne­tra be­came the fifth ap­proved biosim­i­lar to Neu­las­ta on Fri­day, snag­ging a win in neu­trope­nia, a con­di­tion com­mon among chemother­a­py pa­tients where neu­trophils, a type of white blood cell that fights in­fec­tion, are too low.

As of last sum­mer, the list price of Neu­las­ta was more than $6,400 per dose. It’s de­signed to be tak­en in a sin­gle dose per chemother­a­py cy­cle. Am­neal de­clined to re­veal how much it in­tends to charge for Fly­ne­tra in an email to End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.